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Learning Objectives: Cirrhosis 
• Identify and treat /prevent cirrhosis or its progression (mx  etiology).
• Preventive measures:
• Vaccinations
• Nutrition
• Cancer screening/surveillance
• Manage key complications: 
• Ascites
• Renal failure
• Hepatic encephalopathy
• Infection
• HCC
• Varices
• Transplant indications and assessment.
Cirrhosis is end stage of chronic liver 
disease of different etiologies
• HCV, Alcohol NASH most 
common
• Characterized by bridging 
fibrosis and nodules in biopsy
• Compensated cirrhosis may 
be asymptomatic
• Decompensated disease has 
50 -80% 5 year mortality 
• 12th most common cause of  
death in US 
• Rising burden: HCV, HCC, 
Obesity
Suspect CLD if LFTs are abnormal or Risk 
Factors are present
• Alcohol
• Obesity
• Percutaneous exposure to blood. 
• Birth Cohort
• Blood products < 1992, 
• Tattoos,  
• Clotting factors < 1987, 
• Hemodialysis, 
• Needle sticks in HCW, 
• Shared needles with Injection drug 
use, 
• Shared straws with nasal drug use, 
• Incarceration, 
• health care with poor infection 
control
• HBV:  Endemic areas
Identifying Cirrhosis in Primary Care 
Setting
• Early cirrhosis is asymptomatic
• Suspect Liver disease/cirrhosis 
if 
• there are risk factors (Alcohol, 
Viral, Metabolic syndrome, FH)
• Spider nevi, palmar erythema, 
Terry’s nails, gynecomastia 
Dupeytrens contractures, firm 
sharp edged liver, splenomegaly. 
• Persistently abnormal liver tests 
(especially AST > ALT) 
• LOW PLATELETS 
Establish Cirrhosis with Liver Biopsy 
(specialist/Radiology) or Non-invasively
• Liver BX is invasive, costly, with risk 
and poorly accepted 
• Alternatives to liver Bx: 
• APRI score  = (AST/40)/Plts*100
• Fib-4 score = (AST*Age)/(Plts*√(ALT))
• Fibrosure – blood test
• Fibroscan: blind elastic recoil US
• US (enhanced shear wave) – augmented U/S test
• MRE – Magnetic Resonance Elastography
• Stage 3-4 fibrosis /cirrhosis Rule of 12: 
• Spleen > 12 cm
• Portal Vein > 12 mm
• Platelets < 12 ^2 (144)

Initial Management of the Cirrhotic Patient Includes 
General Health, Education and Secondary Prevention 
1. Identify and Treat Etiology
2. Identify and manage co-mobidities  that may lead to progression 
(alcohol, HIV  obesity )
3. Health education and secondary prevention. (HBV HCV Genetic 
etc)
4. Vaccination against flu and pneumonia, hepatitis A and B virus
5. Treat associated conditions (nutrition, diabetes, osteoporosis, 
malnutrition.)
• Promote family and cohabitants’ participation to primary prevention and 
help remove barriers/ impediments to transplant
• substance dependence 
• Social support
• Identify and correct medical issues 
Education and intervention to reduce 
progression 
1. Establish etiology and comorbidities (HIV HBV HCV )
2. Abstinence /cessation of alcohol consumption 
3. Obesity
4. Establish degree of fibrosis to determine the need for 
initiating additional screening measures (eg, 
hepatocellular carcinoma [HCC] screening). 
5. Make sure patient is treated for any treatable etiology 
(refer, if you do not treat)
Treating the Disease May Reverse  
Cirrhosis or Stop Progression
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Treating Hepatitis B 
Treat Cause of Liver Disease
• Alcoholic liver disease
• Hepatitis B: Tenofovir, entecavir. 
• Treat HCV:  Oral, non Interferon based treatments 
• Autoimmune hepatitis
• Hemochromatosis: phlebotomy.
• PBC: Urso/budesonide/MTX
Important to establish the diagnosis accurately wherever possible

General Measures
• Manage Substance dependence: 
• Obesity
• Social:  Caregiver support: especially for hepatic 
encephalopathy 
• Debility: conditioning (physical therapy)
General Measures:  Immunizations and 
Nutrition
• Cirrhotic patients are Immune compromised and have 
special vaccination requirements (same as >65) 
• Hepatitis A
• Hepatitis B
• Pneumococcal: PConjugateV13 or PPolysaccherideV23 should 
receive a single dose of PCV13 followed by a dose of PPSV23 at 
least 8 weeks later. PPSV23, at least 5 years after the most recent 
dose of PPSV23.
• Annual Influenza 
(http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html
accessed 4/14/15)
• Frequent small meals
• Do not skip meals
• Bedtime ensure Plus or 
snack
• Protein: 1-2 g/kg BW-
Do Not restrict for HE. 
• Na restriction < 
2000mg/d for ascites
• Fluid Restriction if 
dilutional hyponatremia
Lindsay D. Plank et al Nocturnal Nutritional Supplementation Improves Total Body Protein Status of patients with Liver Cirrhosis: a 
Randomized 12-Month Trial HEPATOLOGY 2008;48: 557-566
Verboeket-van de Venne WP,. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food 
intake. Gut. 1995;36(1): 110-116
Cirrhosis: Protein Calorie and Micronutrient 
deficiency, and Catabolic in Post-Absorptive State
Improved Total Body Protein with 
16oz  Ensure + (474 cc, 26g protein 710 kcal)
HCC Surveillance  Every 6 months (US and 
AFP)- 3-5% Annual HCC Incidence in Cirrhosis
HCC screening in Cirrhosis
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On Waiting list
• No cirrhosis:
• Chronic hepatitis B carriers: males aged 40 y and females aged 50 y
• family history of hepatocellular cancer in chronic hepatitis B.
Surveillance algorithm
Figure. A proposed liver ultrasound algorithm for surveillance of 
hepatocellular carcinoma.
Gish, R. ,Gastroenterology & Hepatology, 
2014; 10;2:121-123. 
a. See LI-RADS at http://www.acr.org/Quality-
Safety/Resources/LIRADS.
b. Blood tests AFP-L3/DCP (HCC serum biomarkers).
c. AASLD Guidelines 2009.

Prognosis: MELD and Child Score
MELD Model for End Stage Liver 
Disease:10X [0.957  Ln (Creat [mg/dL]) 
+ 0.378  Ln(Total Bili [mg/mL]) + 1.120  
Ln(INR) + 0.643)]
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http://www.unos.org/resources/meldPeldCalculator.asp
Prognosis is Poor  After Index Event:  Liver 
Transplant Evaluation 
• Liver transplant evaluation in all patients with 
decompensated liver disease (Child’s≥ B).
• compensated cirrhosis: 91% 5 year survival.  
• If index event: (Bleed, ascites, HE, renal insufficiency): <50% 5yr 
survival
(Fattovitch Gastro 97; 112: 463)
Absolute Contra-indications to TP : 
competing risks of Death
• Uncontrolled infection
• Extra-hepatic malignancy
• Active substance or alcohol dependence.
• Severe cardiopulmonary disease. 
• Severe pulmonary hypertension.
• Inability to follow immunosuppressive therapy.
Relative Contra-indications: relatively 
competing risks of death
• Advanced Hepatocellular carcinoma (>Stage 3A)
• Cholangiocarcinoma (except stage 1)
• Advanced age (>70yrs)
• Portal vein thrombosis.
• Insufficient social support.  
• HIV : 
• In selected HIV-infected recipients post transplant survival similar 
to that of HIV-negative recipients.
• Survival without transplant worse
• OLT considered if there is no history of opportunistic infections or 
neoplasms, CD4 cell count >100 cells/mm3, and plasma HIV viral 
load suppressible with antiretroviral treatment.

Treat Complications: 
• Ascites
• Spontaneous Bacterial Peritonitis 
• Varices/ prevent Hemorrhage
• Hepatic Encephalopathy
Ascites Management
• Diagnostic paracentesis: in every patient. (TP, Alb Cell 
Count Diff (Triglycerides).  
• Dietary salt restriction (Education)
Fluid loss depends on negative sodium balance (water 
loss follows)
• 2g sodium/day (88mmol)  
• Diuretics 
• Spironolactone 100 –300 (400) mg/day and 
• Furosemide 40-160 (240) mg/day
Large Volume Paracentesis
• Indications:
• Discomfort.
• Dyspnea.
• Tense ascites (hemodynamic improvement).
• Renal insufficiency (compartment syndrome).
• Refractory ascites
• Up to 5 liters may be safely removed sans albumin.  
However, preferable to use 8g albumin IV per liter ascites 
removed.
PPS: Albumin Vs D70 Vs PGL
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PPS: Progressive rise in Renin and very high mortality

Transjugular Intrahepatic 
Portosystemic shunting Versus 
Paracentesis Plus albumin for 
Refractory Ascites in Cirrhosis 
GINE`S. 
GASTROENTEROLOGY 
2002;123:1839–1847
The North American Study for 
the treatment of Refractory 
Ascites. 
GASTROENTEROLOGY 
2003;124:634–641
Refractory Ascites Equally Managed 
Using TIPS or Taps. Stop Beta Blockers.
Deleterious effects of beta-blockers on survival in patients 
with cirrhosis and refractory ascites. Sersté T. Hepatology. 
2010 Sep;52(3):1017-22
Sodium Restriction is for Hypervolemia, 
Water restriction is for Hyponatremia
• RAAS and increased 
aldosterone
• Urine [Na] < 70 
Na:K < 1
• Hyponatremia: 
hypervolemic dilutional 
due to AVP
• Restrict water for NA< 
124. 

Spontaneous Peritonitis
• Often present with:
• Encephalopathy,  GI bleeding,  diarrhea, renal 
impairment  non-specific symptoms of infection.
• May not have.
• Peritoneal signs, fever, pain.
• Prognosis.
• 50% mortality in 1 year.
• Two thirds have recurrence in 1 year.
• DP: admission, (in hospital for any 
deterioration or bleed)
SBP Laboratory
T e s t  R e s u l t  I n t e r p r e t a t i o n  
 
Polymorphonuclear  
> 500/mm3 SBP (97% specific) 
cell count >250 <500 SBP (95% specific) 
Fluid culture (blood culture 
bottle) 
Positive SBP 
 
SBP Treatment
• Antibiotics
• Albumin (1.5g/kg bw day 1, and 1g/kgbw day 3)
Treatment SBP: Antibiotics
• Empiric therapy initiated at time of diagnosis.
• Cefotaxime 2g q 8-12hrs. (Ceftriaxone protein 
bound diminished penetration) 
• May narrow spectrum once sensitivities are 
available
• Treatment: 5 days (similar outcome to 10 day 
therapy)
SBP: Albumin 1.5g/kg D1;1g/kg D3
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SBP Prophylaxis:  Indications
• Previous episode of SBP (1 yr 40-70% 
recurrence)
• Ascites total protein < 1g/dl (20-40% incidence  
in 1 year)
• Bilirubin > 2.5 mg/dl (1 yr 43%)
• If NO prior SBP, alb>1g/dl and bili< 2.5: risk for 
SBP 
• 1year 0% 
• 3 year 3%
SBP Prophylaxis
• Antibiotic choices (all given po)
• Norfloxacin, 400mg/d; Fluoro-quinolone resistance possible: local 
resistance pattern
• Trimethoprim-cotrimoxazole DS 5 days/week
• Meta-analysis:  Survival advantage 
• Life expectancy after SBP: 1 yr 30-50% 2yr 25-30%)

LONGACRE & GARCIA-TSAO Clin Liver Dis 10 (2006) 613–625
Algorithm for Prevention of Variceal 
Hemorrhage in Cirrhosis 
Antibiotic Choice in GI Bleeder
Proven infections
Possible infections
Antibiotic choice: IV gives better levels.  Choice depends on likely organisms 
(resistance patterns etc.  
Oral Norflox and Levoflox no longer antibiotics of choice. 

Hepatic Encephalopathy
• A spectrum of reversible neuropsychiatric abnormalities in 
patients with liver disease1,2 or portosystemic shunting3
• Symptoms may range from subtly altered mental status to 
deep coma4,5
• Marked by alternating periods of acute exacerbation and 
remission6
• Occurs in up to ~50%7 to 70%8 of patients with cirrhosis
1. Blei and Córdoba. Am J Gastroenterol. 2001;96:1968-1976. 2. Mullen et al. Semin Liver Dis. 2007;27(suppl 2):32-48. 3. Mas. 
Digestion. 2006;73(suppl1):86-93. 4. Riordan and Williams. N Engl J Med. 2010;362:1140-1142. 5. de Melo et al. Am J Health-Syst
Pharm. 2008;65:818-822. 6. Merck. http://www.merck.com/mmhe/sec10/ch135/ch135f.html?qt=hepatic encephalopathy&alt=sh. 
Accessed April 6, 2010. 7. Guevera et al. Am J Gastroenterol. 2009;104:1382-1389. 8. Prasad et al. Hepatology. 2007;45:549-559. 
Delirium or Neuropsychiatric Changes in 
Cirrhotic possibly dt Hepatic Encephalopathy
• Rule out other etiologies of delirium or coma (Alcohol, 
sedatives, Drugs, Electrolyte abnormalities, 
hypoglycemia, subdural hematoma, seizures)
• Establish precipitant 
• Hypovolemia, Hypokalemia (too much lactulose), infection, GI 
Bleed, Over diuresis, constipation, dietary protein excess (red 
meat)
• Supportive care (fall precautions, monitoring, IV fluids)
• Treat/remove precipitant
• Lactulose (Avoid overdosing: diarrhea is counter 
productive)
• Rifaximin 550 bid. 

Minimal Hepatic Encephalopathy (Covert) does 
not have overt signs but is debilitating 
• Combination of psychometric test (number connection 
tests (NCTs) A and B, the digit symbol test, and the block 
design test,+  computerized psychometry, critical flicker 
frequency test, inhibitory control.
• It is common and affects quality of life
• Increases risk of accidents. 
Bajaj JS , Navigation skill impairment:another dimension of the driving 
difficulties in minimal hepatic encephalopathy. Hepatology 2008 ; 47 : 596 – 604
Diagnosis MHE
• Combination of psychometric test (number connection 
tests (NCTs) A and B, the digit symbol test, and the block 
design test,+  computerized psychometry, critical flicker 
frequency test, inhibitory control.
• Abnormal tests predict impaired navigational skills in 
cirrhotic patients tested in a driving simulator. 
Bajaj JS , Navigation skill impairment:another dimension of the driving 
difficulties in minimal hepatic encephalopathy. Hepatology 2008 ; 47 : 596 – 604
Minimal Hepatic Encephalopathy increases 
Driving Risk and reduces QOL. 
Treatment MHE
• Non-absorbable disaccharide lactulose and 
probiotics are effective. Antibiotics improve MHE. 
• The non-absorbed and safe antibiotic rifaximin 
has now been shown to improve psychometric 
test performance scores and concomitantly 
improve HRQOL in patients with MHE. 
Prasad S Lactulose improves cognitive functions and HRQOL in minimal hepatic 
encephalopathy . Hepatology 2007 ; 45 : 549 – 59
Sidhu S. Rifaximin improves Psychometric Performance and Health Related Quality of Life in Patients 
with Minimal Hepatic Encephalopathy (The RIME trial) .Am J Gastroenterol 2011;106:307–16

